GET DAILY SIGNALSBillionToOne (BLLN) Delivers Solid Q3 2026 Results with 47% Revenue Growth
Key Takeaways
- BillionToOne reported third-quarter 2026 revenue of $122.98 million, up 47% year over year and above consensus estimates of roughly $115.8 million.
- Diluted earnings per share (EPS) came in at $0.32, topping the consensus estimate of about $0.30, with net income of $17.4 million.
- Management raised its full-year 2026 revenue outlook to a range of $460 million to $470 million, up from $450 million to $465 million, implying 51% to 54% growth.
- Prenatal revenue reached $106 million (up 42% year over year), while oncology revenue nearly doubled to $17 million (up 96% year over year).
- Total test volume grew 25% year over year to approximately 206,000 tests, with sequential growth in both prenatal and oncology segments.
- The company plans to launch Northstar Clear, its tissue-free MRD (minimal residual disease) test, on December 15, 2026.
- For more context, explore the company's Major News, Today's Price Move, Price Targets, and Forecast pages to track the latest developments.
- Looking for broader market ideas? Explore Trending AI Robots to discover automated strategies across the market.
Why This Quarter Matters for BillionToOne
BLLN went public in November 2025 and has drawn steady attention in the precision diagnostics space, where it competes with names such as Natera, Guardant Health, and Illumina. The third-quarter results provide a useful checkpoint on whether the company can maintain rapid revenue expansion while remaining GAAP profitable, something uncommon in diagnostics. Its prenatal business, built around the UNITY tests, and the expanding Northstar oncology lineup are the main drivers investors are tracking. Volume trends, pricing, and margin progress all factor into the longer-term story, and the raised guidance plus new clinical data on Northstar Response give the report added weight.
Breaking Down the Reported Numbers
For the quarter ended September 30, 2026, BLLN posted total revenue of $122.98 million, a 47% increase from $83.5 million a year earlier and ahead of the roughly $115.8 million consensus. Gross profit reached $87.1 million for a margin near 71%. Net income was $17.4 million, producing diluted EPS of $0.32 versus the expected $0.30.
Growth came from both sides of the business. Prenatal revenue rose 42% to $106 million, while oncology revenue jumped 96% to $17 million. Overall test volume climbed 25% year over year to about 206,000 tests. Management lifted full-year 2026 revenue guidance to $460 million to $470 million from the prior $450 million to $465 million range, which points to 51%–54% growth over 2025. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and What Investors Are Watching
Shares of BLLN have shown volatility around earnings releases. The prior quarter saw a sharp one-day drop despite decent fundamentals, reminding investors how sensitive the name can be to headline beats and forward commentary. Entering this report, the stock sat near the middle of its 52-week range with analysts generally constructive on the growth path. The revenue and EPS beats plus the guidance increase should register as positive signals. Still, focus will turn to margin sustainability, oncology uptake, and readiness for the upcoming Northstar Clear launch as investors weigh whether the valuation holds up.
Key Items on the Horizon
The December 15, 2026 launch of Northstar Clear, the company’s tissue-free MRD test, stands out as the next major catalyst. Management sees MRD as a roughly $30 billion annual opportunity, and the new test will broaden the Northstar portfolio into earlier and later stages of cancer care. Investors will also track Medicare coverage progress for Northstar Response, the treatment-monitoring assay. Recent head-to-head data showed it performing on par or better than a tumor-informed rival, which could help with reimbursement and adoption.
On the financial side, attention will stay on whether gross margins can hold near current levels as oncology, which carries higher per-test costs, becomes a larger revenue contributor. Volume growth, average selling prices, and operating expense control will determine if GAAP profitability can continue alongside heavier spending on R&D and sales expansion. Competitive pressure in prenatal screening and liquid biopsy remains another ongoing factor.
How I Use Tickeron’s AI Screener for Research
When I want to quickly compare BLLN against peers or spot other names with similar growth profiles, I turn to Tickeron’s AI Screener. The tool lets me apply filters for revenue trends, margins, and technical signals in one place, which helps narrow ideas before diving deeper into individual reports. It has become a regular part of my routine for keeping an eye on the diagnostics sector without spending hours on manual searches.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for BLLN turns positive, indicating new upward trend
BLLN saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator turned positive. In 19 of the 20 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for BLLN just turned positive on October 21, 2026. Looking at past instances where BLLN's MACD turned positive, the stock continued to rise in 9 of 10 cases over the following month. The odds of a continued upward trend are 90%.
BLLN moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BLLN crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 1 of 1 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +5.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where BLLN advanced for three days, in 47 of 53 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 11 of 13 cases where BLLN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BLLN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
BLLN broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BLLN entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 43 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating fairly steady price growth. BLLN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.709) is normal, around the industry mean (65.986). BLLN has a moderately high P/E Ratio (132.327) as compared to the industry average of (3.066). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (12.195) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BLLN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalSpecialties
Advertisement